Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus‐like Disease in MRL/lpr Mice

Abstract

ObjectivesEZH2 regulates B cell development and differentiation. We previously demonstrated increased EZH2 expression in peripheral blood mononuclear cells from lupus patients. The goal of this study was to evaluate the role of EZH2 expression in B cells in the pathogenesis of lupus.MethodsWe generated an MRL/lpr mouse with floxed Ezh2, which was crossed with CD19‐Cre mice to examine the effect of B cell EZH2 deficiency in MRL/lpr lupus‐prone mice. Differentiation of B cells was assessed using flow cytometry. Single‐cell RNA sequencing and single‐cell B cell receptor sequencing were performed. In vitro B cell culture with an X‐box binding protein 1 (XBP1) inhibitor was performed. EZH2 and XBP1 messenger RNA levels in CD19+ B cells isolated from lupus patients and healthy controls were analyzed.ResultsWe show that Ezh2 deletion in B cells significantly decreased autoantibody production and improved glomerulonephritis. B cell development was altered in the bone marrow and spleen of EZH2‐deficient mice. Differentiation of germinal center B cells and plasmablasts was impaired. Single‐cell RNA sequencing showed that XBP1, a key transcription factor in B cell development, is down‐regulated in the absence of EZH2. Inhibiting XBP1 in vitro impairs plasmablast development similar to EZH2 deficiency in mice. Single‐cell B cell receptor RNA sequencing revealed defective immunoglobulin class‐switch recombination in EZH2‐deficient mice. In human lupus B cells, we observed a strong correlation between EZH2 and XBP1 messenger RNA expression levels.ConclusionEZH2 overexpression in B cells contributes to disease pathogenesis in lupus.image